NetraMark Presents AI-Driven Advances in Precision Psychiatry to Enhance Clinical Trial Designs at Joint Autumn Conference

Core Insights - NetraMark Holdings Inc. is leveraging its AI technology, NetraAI, to enhance clinical trials in the pharmaceutical industry, particularly for major depressive disorder (MDD) [1][10] Group 1: Presentation Highlights - At the ISCTM Autumn conference and ECNP Congress, NetraMark showcased two significant applications of its technology, focusing on ketamine and escitalopram trials [1][5] - The first presentation demonstrated how NetraAI identified distinct patient responder subgroups in ketamine trials, revealing that ketamine responders had unique baseline characteristics compared to placebo responders [2][3] - The second presentation introduced a novel algorithm that improved predictive accuracy in heterogeneous MDD trials, specifically for escitalopram response, by identifying a compact feature set related to anhedonia and mood [5][6] Group 2: Key Findings - In the ketamine trial, responder subgroups diverged significantly from placebo responders by the second infusion, indicating that ketamine's efficacy is not merely due to functional unblinding [4][8] - NetraAI's analysis in the CAN-BIND trial reduced clinical variables from 718 to 8 key variables, enhancing prediction accuracy and identifying a subgroup of highly predictive responders [9][7] - The technology revealed a genetic signature linked to neuroplasticity, allowing for a 91% accuracy in predicting treatment success when retrained on specific features [17] Group 3: Implications for Clinical Trials - NetraAI's capabilities can help overcome traditional barriers in CNS drug development by improving patient stratification, reducing placebo-related noise, and enhancing predictive modeling [10][12] - The advancements in distinguishing true pharmacologic effects from placebo responses represent a significant step forward in the design and interpretation of psychiatric and CNS trials [11][12] - As precision medicine becomes increasingly important, NetraMark's innovations provide a robust toolkit for pharmaceutical companies to uncover meaningful patient subgroups and accelerate drug development timelines [12][14]